BET 3: emergency management of anthracycline extravasation.
A short cut review was carried out to establish whether intravenous dexrazoxane reduces the risk of tissue necrosis after extravasation of the chemotherapy agent anthracycline. One paper directly addressed the question. The clinical bottom line is that intravenous dexrazoxane appears to be safe and may reduce the risk of tissue necrosis after extravasation of anthracycline.
Central Manchester NHS Foundation Trust, Manchester, UK.
David
D
Drake
D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D002614:Chelating Agents / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects*; D004636:Emergency Service, Hospital; D005119:Extravasation of Diagnostic and Therapeutic Materials / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D011929:Razoxane / Q000627:therapeutic use
D000903:Antibiotics, Antineoplastic; D002614:Chelating Agents; D011929:Razoxane; D004317:Doxorubicin